Compare BCS & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCS | A |
|---|---|---|
| Founded | 1690 | 1999 |
| Country | United Kingdom | United States |
| Employees | 98141 | N/A |
| Industry | Commercial Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5B | 39.8B |
| IPO Year | N/A | 1999 |
| Metric | BCS | A |
|---|---|---|
| Price | $20.97 | $111.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 16 |
| Target Price | N/A | ★ $161.06 |
| AVG Volume (30 Days) | ★ 8.2M | 2.2M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 2.16% | 0.91% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $4,472,000,000.00 |
| Revenue This Year | $15.98 | $8.42 |
| Revenue Next Year | $4.36 | $6.12 |
| P/E Ratio | ★ $10.92 | $105.57 |
| Revenue Growth | N/A | ★ 6.43 |
| 52 Week Low | $12.14 | $96.43 |
| 52 Week High | $27.70 | $160.27 |
| Indicator | BCS | A |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 28.25 |
| Support Level | $20.71 | N/A |
| Resistance Level | $21.02 | $122.91 |
| Average True Range (ATR) | 0.63 | 2.49 |
| MACD | -0.19 | -0.15 |
| Stochastic Oscillator | 13.23 | 9.10 |
Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; Barclays UK (retail), UK corporate bank, private bank and wealth management, investment bank, and US consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The US consumer bank includes a co-branded credit card and unsecured lending business. The investment bank offers global markets, financing, and advisory services.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.